Literature DB >> 8823177

Inhibition of TEM-2 beta-lactamase from Escherichia coli by clavulanic acid: observation of intermediates by electrospray ionization mass spectrometry.

R P Brown1, R T Aplin, C J Schofield.   

Abstract

Clavulanic acid, the therapeutically important inhibitor of beta-lactamases containing a nucleophilic serine residue at their active sites, inhibits Escherichia coli TEM-2 beta-lactamase via a complex mechanism. Electrospray ionization mass spectrometry (ESIMS) studies revealed that a minimum of four different modified proteins are formed upon incubation of clavulanate with the TEM-2 enzyme. These exhibit mass increments relative to the unmodified TEM-2 beta-lactamase of 52, 70, 88, and 155 Da. Time course studies implied that no long-lived forms of clavulanate-inhibited TEM-2 beta-lactamase retain the carbons of the oxazolidine ring of clavulanate. The absence of a 199 Da increment to unmodified TEM-2 suggests rapid decarboxylation of clavulanate upon binding to the enzyme. Proteolytic digestions of purified forms of clavulanate inhibited TEM-2 beta-lactamase followed by analyses using high-performance liquid chromatography coupled to ESIMS (HPLC-ESIMS) and chemical sequencing were used to provide positional information on the modifications to the enzyme. Increments of 70 and 80 Da increments were shown to be located in a peptide containing Ser-70. A further 70 Da mass increment, assigned as a beta-linked acrylate, was localized to a peptide containing Ser-130. A mechanistic scheme for the reaction of clavulanate with TEM-2 beta-lactamase is proposed in which acylation at Ser-70 and subsequent decarboxylation is followed either by cross-linking with Ser-130 to form a vinyl ether or by reformation of unmodified enzyme via a Ser-70 linked (hydrated) aldehyde. Purified cross-linked vinyl ether was observed to slowly convert under acidic conditions to a Ser-70 linked (hydrated) aldehyde with concomitant conversion of Ser-130 to a dehydroalanyl residue.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8823177     DOI: 10.1021/bi961044g

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  28 in total

1.  Effects of Ser130Gly and Asp240Lys substitutions in extended-spectrum beta-lactamase CTX-M-9.

Authors:  C Aumeran; C Chanal; R Labia; D Sirot; J Sirot; R Bonnet
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

2.  Rational design of a beta-lactamase inhibitor achieved via stabilization of the trans-enamine intermediate: 1.28 A crystal structure of wt SHV-1 complex with a penam sulfone.

Authors:  Pius S Padayatti; Anjaneyulu Sheri; Monica A Totir; Marion S Helfand; Marianne P Carey; Vernon E Anderson; Paul R Carey; Christopher R Bethel; Robert A Bonomo; John D Buynak; Focco van den Akker
Journal:  J Am Chem Soc       Date:  2006-10-11       Impact factor: 15.419

3.  Molecular characterization of TEM-59 (IRT-17), a novel inhibitor-resistant TEM-derived beta-lactamase in a clinical isolate of Klebsiella oxytoca.

Authors:  H Bermudes; F Jude; E B Chaibi; C Arpin; C Bebear; R Labia; C Quentin
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

4.  Importance of position 170 in the inhibition of GES-type β-lactamases by clavulanic acid.

Authors:  Hilary Frase; Marta Toth; Matthew M Champion; Nuno T Antunes; Sergei B Vakulenko
Journal:  Antimicrob Agents Chemother       Date:  2011-01-10       Impact factor: 5.191

5.  Understanding the molecular determinants of substrate and inhibitor specificities in the Carbapenemase KPC-2: exploring the roles of Arg220 and Glu276.

Authors:  Krisztina M Papp-Wallace; Magdalena A Taracila; Kerri M Smith; Yan Xu; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2012-06-11       Impact factor: 5.191

6.  Why tazobactam and sulbactam have different intermediates population with SHV-1 β-lactamase: a molecular dynamics study.

Authors:  Rui Li; Yeng-Tseng Wang; Cheng-Lung Chen
Journal:  J Mol Model       Date:  2013-03-01       Impact factor: 1.810

7.  Penicillin sulfone inhibitors of class D beta-lactamases.

Authors:  Sarah M Drawz; Christopher R Bethel; Venkata R Doppalapudi; Anjaneyulu Sheri; Sundar Ram Reddy Pagadala; Andrea M Hujer; Marion J Skalweit; Vernon E Anderson; Shu G Chen; John D Buynak; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2010-01-19       Impact factor: 5.191

8.  The role of a second-shell residue in modifying substrate and inhibitor interactions in the SHV beta-lactamase: a study of ambler position Asn276.

Authors:  Sarah M Drawz; Christopher R Bethel; Kristine M Hujer; Kelly N Hurless; Anne M Distler; Emilia Caselli; Fabio Prati; Robert A Bonomo
Journal:  Biochemistry       Date:  2009-06-02       Impact factor: 3.162

9.  Haemophilus influenzae bla(ROB-1) mutations in hypermutagenic deltaampC Escherichia coli conferring resistance to cefotaxime and beta-lactamase inhibitors and increased susceptibility to cefaclor.

Authors:  Juan-Carlos Galán; María-Isabel Morosini; María-Rosario Baquero; Milagro Reig; Fernando Baquero
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

10.  Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate.

Authors:  Jean-Emmanuel Hugonnet; John S Blanchard
Journal:  Biochemistry       Date:  2007-10-04       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.